Liestal, Switzerland, October 19, 2011 - Santhera Pharmaceuticals (SIX: SANN) announced today that it will present data from the 2-year open-label study (DELPHI-E study) evaluating Catena® for the treatment of Duchenne Muscular Dystrophy [1], one of the most common and devastating types of muscular dystrophy. The findings indicate that Catena® slowed the decline in respiratory function compared to the expected natural history in patients with Duchenne Muscular Dystrophy. Data from this study are in agreement with and confirm data from a randomized controlled study (DELPHI study) of 12 months duration [2]. The poster presentation will be given at the 16th International Congress of the World Muscle Society in Almancil, Portugal on October 21, 2011.
References
[1] Buyse G.M., Goemans N., van den Hauwe M., Thijs D., Wei Hui, Rummey C., Meier T., Mertens L.: Results from a two-year open label intervention study with idebenone (Catena®) in patients with Duchene Muscular Dystrophy. Poster presentation at the 16th International Congress of the World Muscle Society in Almancil, Portugal, from October 18 to 22, 2011.
[2] Buyse G.M., Goemans N., van den Hauwe M., Thijs D., de Groot I.J.M., Schara U., Ceulemans B., Meier T., Mertens M.: Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized placebo-controlled trial. Neuromuscular Disorders 2011; 21:396-405.
Subscribe To Posts